Add-On Bifidobacterium bifidum Supplement in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Week Randomized Double-Blind Placebo-Controlled Clinical Trial
Wang LJ, Tsai CS, Chou WJ, Kuo HC, Huang YH
Published in Nutrients
Methodology
Twelve-week randomized double-blind placebo-controlled add-on trial of B. bifidum Bf-688 (5 x 10^9 CFU/day) versus placebo in children with ADHD on stable methylphenidate, with CPT/CATA testing and faecal microbiome sequencing.
Key Findings
The Bf-688 group, but not placebo, showed significant improvements in CPT omission errors and Hit reaction time on both CPT and CATA, alongside an increased Firmicutes/Bacteroidetes ratio.
Conclusions
Add-on B. bifidum Bf-688 may enhance neuropsychological performance in medicated children with ADHD, possibly via gut microbiome changes.
Limitations
Small single-country sample; add-on design on top of stimulant medication; computerised attention tests rather than clinical rating scales as primary endpoints.
Supplements Studied
The group receiving Bf-688 supplementation, but not the placebo group, exhibited significant improvements in omission errors in CPT as well as Hit reaction time in both CPT and CATA.
Outcomes Measured
Significant improvements in omission errors in CPT as well as Hit reaction time in both CPT and CATA.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Academic/government funding reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.